Clinical Trials Logo

Iris Melanoma clinical trials

View clinical trials related to Iris Melanoma.

Filter by:

NCT ID: NCT00288041 Completed - Recurrent Melanoma Clinical Trials

Bortezomib, Paclitaxel, and Carboplatin in Treating Patients With Metastatic Melanoma

Start date: October 2005
Phase: Phase 2
Study type: Interventional

This phase II trial is studying how well giving bortezomib together with paclitaxel and carboplatin works in treating patients with metastatic melanoma. Bortezomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Bortezomib may help paclitaxel and carboplatin kill more tumor cells by making tumor cells more sensitive to these drugs

NCT ID: NCT00243061 Completed - Recurrent Melanoma Clinical Trials

AZD2171 in Treating Patients With Recurrent or Stage IV Melanoma

Start date: January 2006
Phase: Phase 2
Study type: Interventional

This phase II trial is studying how well AZD2171 works in treating patients with recurrent or stage IV melanoma. AZD2171 may stop the growth of tumor cells by blocking blood flow to the tumor and by blocking some of the enzymes needed for cell growth.

NCT ID: NCT00121225 Completed - Recurrent Melanoma Clinical Trials

Vorinostat in Treating Patients With Metastatic or Unresectable Melanoma

Start date: September 2005
Phase: Phase 2
Study type: Interventional

This phase II trial is studying how well vorinostat works in treating patients with metastatic or unresectable melanoma. Vorinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.

NCT ID: NCT00089063 Completed - Stage IV Melanoma Clinical Trials

Vaccine Therapy With or Without Sargramostim in Treating Patients Who Have Undergone Surgery for Melanoma

Start date: June 2004
Phase: Phase 2
Study type: Interventional

This randomized phase II trial is studying vaccine therapy and sargramostim to see how well they work compared to vaccine therapy alone in treating patients who have undergone surgery for stage IIB, stage IIC, stage III, or stage IV melanoma. Vaccines made from peptides may make the body build an immune response to kill tumor cells. Colony-stimulating factors such as sargramostim increase the number of immune cells found in bone marrow or peripheral blood. Combining vaccine therapy with sargramostim may make a stronger immune response.

NCT ID: NCT00085189 Completed - Recurrent Melanoma Clinical Trials

Vaccine Therapy in Treating Patients With Stage IIC-IV Melanoma

Start date: May 2004
Phase: Phase 2
Study type: Interventional

This pilot phase II trial studies how well giving vaccine therapy works in treating patients with stage IIC-IV melanoma. Vaccines made from melanoma peptides or antigens may help the body build an effective immune response to kill tumor cells